{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:02:11Z","timestamp":1781154131129,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000045","name":"Western Economic Diversification Canada","doi-asserted-by":"publisher","award":["000015836"],"award-info":[{"award-number":["000015836"]}],"id":[{"id":"10.13039\/501100000045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015147","name":"Innovation Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021824","name":"Government of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008921","name":"Ministry of Agriculture - Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127748","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:05:24Z","timestamp":1758024324000},"page":"127748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and immunogenicity of COVAC-2, a Sepivac SWE\u2122 adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Glenn","family":"Hamonic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Pastural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Scruten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"ElSherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Courant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland A.","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Daugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"van Drunen Little-van den Hurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Sanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Gerdts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Racine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127748_bb0005","unstructured":"Organization, W.H. World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > Cases [Dashboard]. https:\/\/data.who.int\/dashboards\/covid19\/cases. [cited 2024 22 May]."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127748_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/idr13020041","article-title":"COVID-19 vaccination in developing nations: challenges and opportunities for innovation","volume":"13","author":"Sheikh","year":"2021","journal-title":"Infect Dis Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2222641","article-title":"The COVID-19 experience in Africa and the Middle East","volume":"55","author":"Bizri","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.vaccine.2025.127748_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127748_bb0025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127748_bb0030","series-title":"Influenza pathogenesis and control - Volume II","first-page":"151","article-title":"Inactivated and adjuvanted influenza vaccines","author":"Del Giudice","year":"2015"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127748_bb0035","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41541-021-00395-4","article-title":"Development of molecular clamp stabilized hemagglutinin vaccines for influenza a viruses","volume":"6","author":"McMillan","year":"2021","journal-title":"npj Vaccines"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127748_bb0045","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.vaccine.2023.03.035","article-title":"Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE\u2122","volume":"41","author":"Xu","year":"2023","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2025.127748_bb0050","doi-asserted-by":"crossref","first-page":"125980","DOI":"10.1016\/j.vaccine.2024.05.028","article-title":"Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern","volume":"42","author":"Garg","year":"2024","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127748_bb0055","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127748_bb0060","series-title":"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials","first-page":"10","author":"U.S. Department of Health and Human Services","year":"2007"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127748_bb0065","first-page":"186","article-title":"Evaluation of the performance of multiple immunoassay diagnostic platforms on the National Microbiology Laboratory SARS-CoV-2 National Serology Panel","volume":"7","author":"Dibernardo","year":"2022","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127748_bb0070","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41541-022-00507-8","article-title":"Affordable SARS-CoV-2 protein vaccines for the pandemic endgame","volume":"7","author":"Triccas","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127748_bb0080","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127748_bb0085","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41541-023-00736-5","article-title":"Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2","volume":"8","author":"Leal","year":"2023","journal-title":"npj Vaccines"},{"issue":"7830","key":"10.1016\/j.vaccine.2025.127748_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127748_bb0100","article-title":"Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study","volume":"4","author":"Akahata","year":"2023","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127748_bb0105","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2025.127748_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.vaccine.2025.127748_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104842","article-title":"Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or \u226556 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"97","author":"Chappell","year":"2023","journal-title":"EBioMedicine"},{"issue":"29","key":"10.1016\/j.vaccine.2025.127748_bb0120","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1016\/j.vaccine.2023.05.015","article-title":"One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): final analysis of a randomized, placebo-controlled phase 1\/2 trial in Japan","volume":"41","author":"Ishikawa","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0125","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1038\/s41598-024-55320-1","article-title":"Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study","volume":"14","author":"Reiter","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0130","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1038\/s41598-023-35662-y","article-title":"Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B","volume":"13","author":"Martin-Orozco","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127748_bb0135","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127748_bb0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"6512","key":"10.1016\/j.vaccine.2025.127748_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127748_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12865-018-0245-0","article-title":"Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation","volume":"19","author":"Younis","year":"2018","journal-title":"BMC Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:37:26Z","timestamp":1778506646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2501045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"alternative-id":["S0264410X2501045X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127748","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of COVAC-2, a Sepivac SWE\u2122 adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127748"}}